Novo Nordisk said it will cut the list prices in the U.S. of two of its insulin drugs, Tresiba (insulin degludec) and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026. Fiasp's price ...
The Centers for Medicare & Medicaid Services (CMS) has selected the first 10 drugs for discussions with pharmaceutical companies about reducing prescription costs under the new Medicare price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results